新京报贝壳财经讯 1月11日，仙乐健康发布公告称，公司已于2026年1月8日召开第四届董事会第十七次 会议，会议审议通过了拟发行H股股票并在香港联合交易所有限公司主板上市的相关议案。公告指出， 此举旨在深化全球化战略布局，利用国际资本市场优势，提高公司资本实力和综合竞争力，加快海外业 务发展，完善境内外双循环格局，巩固行业地位。目前，公司正就发行及上市事宜与相关中介机构展开 商讨，具体细节尚未最终确定。 ...

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]

仙乐健康（300791）(300791.SZ)发布公告，为深化公司全球化战略布局，利用国际资本市场优势，打 造多元化资本运作平台，进一步提高公司资本实力和综合竞争力，以加快海外业务发展，完善境内外双 循环格局，巩固行业地位，公司拟发行境外上市外资股(H股)股票并申请在香港联交所主板挂牌上市。 ...

Core Viewpoint - Xianle Health is planning to issue H-shares and list on the Hong Kong Stock Exchange, marking a significant step in its globalization strategy and potentially becoming the first A+H listed company in the nutrition and health industry [1][2] Group 1: Company Overview - Xianle Health, established in 1993, is a leading global provider of comprehensive solutions for nutrition and health products, offering services that include research and product development, manufacturing, packaging, logistics, and marketing support [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext board on September 25, 2019, becoming the first A-share listed CDMO enterprise in the nutrition and health food sector [1] Group 2: Strategic Focus - The company is focused on the trends of health consumption upgrades and aims to enhance customer service, research innovation, and agile supply chain competitive barriers [1] - Xianle Health is strategically targeting high-potential global markets and is building a global operational network that emphasizes "headquarters empowerment and regional deep cultivation" to drive replicable and scalable business [1] Group 3: Fundraising Purpose - The funds raised from the H-share issuance will be used to optimize production capacity in key regional markets, strengthen core competitiveness, accelerate the construction of new productive forces, supplement working capital, and enhance the company's capital strength and overall influence [2]

Group 1: Macro Insights - The U.S. job market showed good performance in December, with non-farm employment slightly below expectations but an unemployment rate better than expected, indicating overall stability [4] - CPI has risen for four consecutive months, reaching the highest level since March 2023, while PPI has also shown signs of recovery, suggesting a potential upward trend in prices for 2026 [4][16] - The overall market sentiment is influenced by various macroeconomic indicators, with a focus on liquidity, economic performance, and valuation metrics [8][9] Group 2: New Energy Vehicles - The domestic new energy vehicle market continues to thrive, with projected sales for 2026 expected to reach 1,515 million units in China, reflecting a 15% year-on-year increase [17] - The demand for batteries and materials is expected to improve, with a significant increase in global battery demand anticipated [17][19] - Investment recommendations include focusing on key players in the battery sector such as CATL and other midstream material companies [19] Group 3: Wind Power Industry - The domestic wind power demand is steadily increasing, with expectations for offshore wind projects to accelerate as planning progresses [20] - The profitability of domestic wind turbine manufacturers is expected to improve, driven by price increases and export opportunities [20][21] - Investment suggestions include major turbine manufacturers and component suppliers, highlighting the potential for growth in the offshore wind sector [20] Group 4: Real Estate and REITs - The real estate market remains cautious, with land transaction volumes declining but at a slower rate, indicating a potential stabilization [12] - C-REITs have shown positive performance in the secondary market, with specific sectors like municipal water and data centers performing well [27] - Investment strategies focus on identifying quality projects with growth potential in high-demand urban areas [27] Group 5: Chemical Industry - Haohua Technology is positioned as a leading platform in new materials, benefiting from high demand in specialty chemicals and refrigerants [28][29] - The company has seen significant profit growth driven by rising prices in fluorinated chemicals, with expectations for continued upward momentum [29] - Investment recommendations emphasize the potential for growth in commercial aerospace and high-end electronic materials [29][32]

Group 1 - The company has signed a non-binding letter of intent with a potential buyer for the acquisition of 100% equity in Best Formulations PC LLC (BFPC), which is expected to optimize its U.S. business structure and enhance overall profitability and market competitiveness [1] - The divestiture of BFPC is anticipated to significantly narrow losses, with projections indicating a loss of 130 million yuan for the first three quarters of 2025, thus boosting the company's profit performance post-sale [1] Group 2 - The company plans to issue H shares and list on the Hong Kong Stock Exchange, leveraging international capital market advantages to accelerate its globalization strategy and expand overseas markets [2] - Revenue distribution for the first half of 2025 shows significant contributions from various regions: 820 million yuan from mainland China, 760 million yuan from the Americas, 360 million yuan from Europe, and 100 million yuan from other regions, indicating a strong overseas business presence [2] Group 3 - The introduction of AI nutritionists and the JsRight brand aims to provide personalized nutrition solutions, transitioning from a one-size-fits-all approach to tailored health management, aligning with consumer demands for functionality and convenience [3] - The company is expected to strengthen its technological leadership in the "precision nutrition" sector, capturing potential market growth driven by consumer health trends [3] Group 4 - Due to the short-term impact of BFPC's losses on the company's financial statements, profit forecasts have been revised downwards, with expected net profits for 2025-2027 at 310 million, 410 million, and 500 million yuan respectively, reflecting a year-on-year change of -5.5%, +32.5%, and +22.8% [3]

Core Viewpoint - Xianle Health is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to deepen its global strategy and enhance overseas business development [1][2]. Group 1: Company Performance - In 2024, Xianle Health's main business revenue reached 4.184 billion yuan, a year-on-year increase of 17.25%, but revenue in China declined by 10.28% to 1.66 billion yuan [3]. - For the first half of 2025, the company's main business revenue was 2.028 billion yuan, a year-on-year increase of 2.62%, with Chinese revenue at 818 million yuan, showing a decline of 1.63% [3]. - Revenue growth in the Americas and Europe was significant, with increases of 59.56% and 14.25% respectively in 2024, and 4.26% and 21.96% respectively in the first half of 2025 [3]. Group 2: Strategic Initiatives - The company aims to leverage international capital markets through H-share listing to create a diversified capital operation platform [2]. - Xianle Health has been pursuing a globalization strategy since 2016, including the acquisition of Ayanda, a European soft capsule manufacturer, to enhance its market presence in Europe [2]. - The company has established a global supply chain with production bases in China, Germany, the USA, and Thailand, enhancing its local supply capabilities [2]. Group 3: Operational Challenges - Domestic performance is under pressure due to structural changes in the market, with traditional brands facing challenges from new retail and cross-industry pharmaceutical brands [3]. - The company announced a delay in its digital information construction project, extending the expected completion date from December 31, 2025, to December 31, 2026 [3]. - Production capacity utilization rates vary, with domestic soft capsules and gummies at medium to high levels, while the beverage powder capacity is underutilized [4].

Group 1 - TSMC is progressing well with the development of its next-generation 1.4nm process, planning to start risk production in 2027 and gradually ramp up production in 2028. The company expects sales to reach NT$335 billion in December 2025, a year-on-year increase of 20.4%, slightly exceeding market expectations. Cumulative sales for 2025 are projected at NT$3.81 trillion, reflecting a year-on-year growth of 31.6% [2] - OpenAI is advancing audio AI technology and plans to release a more natural real-time voice model in 2026, aiming to replace screen interactions with voice. The company is also investing $1 billion with SoftBank Group in SB Energy to support its growth as a data center developer and operator [2] - Meta has reached agreements with nuclear power suppliers Oklo, Vistra, and TerraPower to potentially acquire up to 6.6 GW of nuclear power capacity by 2035, positioning itself as the largest nuclear energy buyer among tech giants to support its data center operations [2] - Merck is reportedly in talks to acquire cancer drug developer Revolution Medicines for between $28 billion and $32 billion, which would mark a significant transaction in the recent biotech merger wave and enhance its oncology product line [2] Group 2 - Geely Holding is likely to announce an expansion plan in the U.S. within the next 24 to 36 months, with brands like Zeekr and Lynk & Co potentially suitable for the U.S. market, aiming to accelerate its global layout and expand into high-end overseas markets [5] - BAIC New Energy has launched a pilot operation for the Arcfox Alpha S (L3 version) in collaboration with Beijing Mobility, with the first batch of vehicles expected to enter designated areas by Q2 2026, promoting the commercialization of autonomous driving technology [5] - China Resources Microelectronics has signed a strategic cooperation agreement with TCL Industries and Zhonghuan Lianxing, focusing on power devices, smart power modules, and MCUs to enhance competitiveness in the semiconductor supply chain [5] - Tencent's Chief AI Scientist stated that the company has a strong 2C gene and faces challenges in the 2B market in China, indicating a future exploration of differentiated development paths for 2B business [5] - Stone Technology has received approval from the CSRC for its Hong Kong IPO, planning to issue no more than 33.108 million shares, which will further expand its financing channels [6] Group 3 - Samsung Electronics' Galaxy S26 Ultra model will support eSIM and is expected to be released next month, while major tech companies like Google, Microsoft, and Meta are seeking memory supply support from Samsung and SK Hynix due to global memory shortages [11] - Toyota remains the top-selling car brand in Indonesia for 2025, while Tesla has surpassed Toyota in global market capitalization, reflecting ongoing market optimism for the electric vehicle sector and increasing pressure on traditional automakers [11] - Sumitomo Metal Mining is investing in a nickel wet processing plant in Indonesia to build a stable resource supply network, with Japan's nickel metal production expected to reach 106,000 tons by 2025 [11] - BMW Group expects global sales of 2.464 million units in 2025, a slight increase of 0.5% year-on-year, with a 12.5% decline in the Chinese market, while European and U.S. markets show growth of 7.3% and 5.0%, respectively [13] - LVMH is reportedly collaborating with Chinese beauty brand Mao Geping, although specific details of the partnership have not been disclosed, indicating its expansion in the beauty sector [13]

Group 1 - The core viewpoint of the article is that Xianle Health (300791.SZ) plans to issue overseas listed foreign shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to enhance its global strategy and capital strength [1] Group 2 - The company aims to leverage the advantages of international capital markets to create a diversified capital operation platform [1] - The initiative is intended to accelerate the development of overseas business and improve the domestic and international dual circulation pattern [1] - This move is expected to strengthen the company's competitive position within the industry [1]

Key Points - Major asset restructuring plans are underway for several companies, including JiaoYun Co. and Dongzhu Ecology, with significant risks of termination noted for Dongzhu Ecology's restructuring efforts [11][12] - ST KeliDa is set to resume trading on January 12, 2026, following a proposed change in its actual controller [5] - NineLink Technology has terminated its major asset restructuring plans due to disagreements on core transaction terms [6] - Companies like Huazhou Laojiao and others have announced substantial profit distributions and performance forecasts, indicating positive growth trends [8][9][10] Focus Area 1: Asset Restructuring - JiaoYun Co. is planning a major asset swap involving its automotive sales and service segments with assets from its controlling shareholder [11] - Dongzhu Ecology is attempting to acquire control of Kai Rui Xing Tong Information Technology but faces significant termination risks due to valuation disagreements [12] - NineLink Technology has decided to halt its plans to acquire a 51% stake in Chengdu Neng Tong Technology after failing to reach consensus on key transaction details [6] Focus Area 2: Trading Resumption and Risk Warnings - ST KeliDa will resume trading on January 12, 2026, after a proposed change in its actual controller [5] - China First Heavy Industries and Oriental Pearl have issued risk warning announcements regarding their stock trading, highlighting the volatility and lack of revenue from certain projects [3][4] Focus Area 3: Performance Forecasts - Huazhou Laojiao expects a net profit of between 235 million to 271 million yuan for 2025, a significant recovery from a loss in the previous year [8] - China Shipbuilding Defense anticipates a net profit increase of 149.61% to 196.88% for 2025, driven by improved production efficiency and revenue from joint ventures [9] - Daotong Technology projects a net profit of 900 million to 930 million yuan for 2025, reflecting a growth of 40.42% to 45.10% [10]